CN110546167A - 以抗-cd52抗体治疗多发性硬化症 - Google Patents

以抗-cd52抗体治疗多发性硬化症 Download PDF

Info

Publication number
CN110546167A
CN110546167A CN201880026423.7A CN201880026423A CN110546167A CN 110546167 A CN110546167 A CN 110546167A CN 201880026423 A CN201880026423 A CN 201880026423A CN 110546167 A CN110546167 A CN 110546167A
Authority
CN
China
Prior art keywords
dose
patient
antibody
administered
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880026423.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·H·玛戈林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Building A New Co
Genzyme Corp
Original Assignee
Building A New Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Building A New Co filed Critical Building A New Co
Publication of CN110546167A publication Critical patent/CN110546167A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880026423.7A 2017-04-21 2018-04-20 以抗-cd52抗体治疗多发性硬化症 Pending CN110546167A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762488630P 2017-04-21 2017-04-21
US62/488,630 2017-04-21
US201762575119P 2017-10-20 2017-10-20
US62/575,119 2017-10-20
US201862647301P 2018-03-23 2018-03-23
US62/647,301 2018-03-23
PCT/US2018/028616 WO2018195457A2 (en) 2017-04-21 2018-04-20 Treatment of multiple sclerosis with anti-cd52 antibodies

Publications (1)

Publication Number Publication Date
CN110546167A true CN110546167A (zh) 2019-12-06

Family

ID=62117065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026423.7A Pending CN110546167A (zh) 2017-04-21 2018-04-20 以抗-cd52抗体治疗多发性硬化症

Country Status (6)

Country Link
US (2) US20200299399A1 (enExample)
EP (1) EP3612564A2 (enExample)
JP (2) JP7219721B2 (enExample)
CN (1) CN110546167A (enExample)
TW (1) TW201841653A (enExample)
WO (1) WO2018195457A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031626A1 (en) * 2006-09-13 2008-03-20 Bayer Schering Pharma Aktiengesellschaft Treatment of multiple sclerosis (ms) with campath-1h
US20080267954A1 (en) * 2006-09-13 2008-10-30 Margolin David H Treatment of multiple sclerosis (MS)
CN105209495A (zh) * 2013-03-15 2015-12-30 建新公司 抗cd52抗体
US20160184428A1 (en) * 2013-08-01 2016-06-30 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429582A4 (en) * 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
ES2838680T3 (es) * 2014-10-09 2021-07-02 Genzyme Corp Conjugados de anticuerpo-fármaco glucomodificados

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031626A1 (en) * 2006-09-13 2008-03-20 Bayer Schering Pharma Aktiengesellschaft Treatment of multiple sclerosis (ms) with campath-1h
US20080267954A1 (en) * 2006-09-13 2008-10-30 Margolin David H Treatment of multiple sclerosis (MS)
CN105209495A (zh) * 2013-03-15 2015-12-30 建新公司 抗cd52抗体
US20160184428A1 (en) * 2013-08-01 2016-06-30 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郭丽萍;: "多发性硬化的治疗进展" *

Also Published As

Publication number Publication date
US20230167189A1 (en) 2023-06-01
WO2018195457A3 (en) 2018-11-29
JP2023052642A (ja) 2023-04-11
JP7219721B2 (ja) 2023-02-08
US20200299399A1 (en) 2020-09-24
WO2018195457A2 (en) 2018-10-25
JP2020517648A (ja) 2020-06-18
EP3612564A2 (en) 2020-02-26
TW201841653A (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
CN101489573B (zh) 用TACI-Ig融合分子治疗自身免疫疾病的方法
KR102735988B1 (ko) 치료 항체 제제
CN105188751A (zh) 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
WO2014203183A1 (en) Use of a vegf antagonist in treating macular edema
JP2018531927A (ja) てんかんの治療方法
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
KR20170045240A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
WO2024243323A1 (en) Treatment of multiple sclerosis with anti-cd40l antibodies
EP3864053B1 (en) Treatment of rms by switching therapy
CN112312971A (zh) 结合cd123和cd3的双特异性抗体的给药
US20230167189A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
Soelberg Sorensen Intravenous polyclonal human immunoglobulins in multiple sclerosis
CN112512578A (zh) 结合cd123和cd3的双特异性抗体的给药
KR20240046200A (ko) 소아 ms 치료를 위한 오파투무맙
TWI748990B (zh) 用於治療生長激素缺乏症的重組人類生長激素的藥物組合物的應用及其用途
JP2025517856A (ja) １型糖尿病を予防又は遅延させるための方法及び組成物
TW202222829A (zh) 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
CA3153634A1 (en) Methods of treatment using omalizumab
JP2022502380A (ja) 抗ｃｄ１５４抗体の安全な投与を提供する方法
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
TW202517294A (zh) 用於治療多發性硬化症之組成物及方法
KR20250011951A (ko) 인터루킨-17 (il-17) 길항제를 사용한 거대 세포 동맥염의 치료 방법
CN115812079A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法
Cortese et al. Immunomodulatory Therapy for Multiple Sclerosis
HK40051003B (en) Treatment of rms by switching therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191206

WD01 Invention patent application deemed withdrawn after publication